Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Commun ; 14(1): 3367, 2023 06 08.
Article in English | MEDLINE | ID: mdl-37291115

ABSTRACT

Profiling the nascent cellular proteome and capturing early proteomic changes in response to external stimuli provides valuable insights into cellular physiology. Existing metabolic protein labeling approaches based on bioorthogonal methionine- or puromycin analogs allow for the selective visualization and enrichment of newly synthesized proteins. However, their applications are limited as they often require methionine-free conditions, auxotrophic cells and/or are toxic to cells. Here, we introduce THRONCAT, a threonine-derived non-canonical amino acid tagging method based on the bioorthogonal threonine analog ß-ethynylserine (ßES) that enables efficient labeling of the nascent proteome in complete growth media within minutes. We use THRONCAT for the visualization and enrichment of nascent proteins in bacteria, mammalian cells and Drosophila melanogaster. We profile immediate proteome dynamics of B-cells in response to B-cell receptor activation simply by adding ßES to the culture medium, demonstrating the ease-of-use of the method and its potential to address diverse biological questions. In addition, using a Drosophila model of Charcot-Marie-Tooth peripheral neuropathy, we show that THRONCAT enables visualization and quantification of relative protein synthesis rates in specific cell types in vivo.


Subject(s)
Proteome , Threonine , Animals , Proteome/metabolism , Drosophila melanogaster/metabolism , Proteomics , Amino Acids/metabolism , Methionine/metabolism , Mammals/metabolism
2.
Org Biomol Chem ; 19(13): 2856-2870, 2021 04 07.
Article in English | MEDLINE | ID: mdl-33725048

ABSTRACT

Bacterial infections are still one of the leading causes of death worldwide; despite the near-ubiquitous availability of antibiotics. With antibiotic resistance on the rise, there is an urgent need for novel classes of antibiotic drugs. One particularly troublesome class of bacteria are those that have evolved highly efficacious mechanisms for surviving inside the host. These contribute to their virulence by immune evasion, and make them harder to treat with antibiotics due to their residence inside intracellular membrane-limited compartments. This has sparked the development of new chemical reporter molecules and bioorthogonal probes that can be metabolically incorporated into bacteria to provide insights into their activity status. In this review, we provide an overview of several classes of metabolic labeling probes capable of targeting either the peptidoglycan cell wall, the mycomembrane of mycobacteria and corynebacteria, or specific bacterial proteins. In addition, we highlight several important insights that have been made using these metabolic labeling probes.


Subject(s)
Bacterial Proteins/metabolism , Cell Wall/metabolism , Corynebacterium/metabolism , Mycobacterium/metabolism , Peptidoglycan/metabolism , Bacterial Proteins/chemistry , Cell Wall/chemistry , Corynebacterium/chemistry , Host-Pathogen Interactions , Humans , Molecular Conformation , Mycobacterium/chemistry , Peptidoglycan/chemistry
3.
Bioconjug Chem ; 29(3): 587-603, 2018 03 21.
Article in English | MEDLINE | ID: mdl-29378134

ABSTRACT

Toll-like receptors (TLRs) are vital elements of the mammalian immune system that function by recognizing pathogen-associated molecular patterns (PAMPs), bridging innate and adaptive immunity. They have become a prominent therapeutic target for the treatment of infectious diseases, cancer, and allergies, with many TLR agonists currently in clinical trials or approved as immunostimulants. Numerous studies have shown that conjugation of TLR agonists to other molecules can beneficially influence their potency, toxicity, pharmacokinetics, or function. The functional properties of TLR agonist conjugates, however, are highly dependent on the ligation strategy employed. Here, we review the chemical structural requirements for effective functional TLR agonist conjugation. In addition, we provide similar analysis for those that have yet to be conjugated. Moreover, we discuss applications of covalent TLR agonist conjugation and their implications for clinical use.


Subject(s)
Adjuvants, Immunologic/chemistry , Toll-Like Receptors/agonists , Vaccines, Synthetic/chemistry , Adaptive Immunity , Adjuvants, Immunologic/chemical synthesis , Adjuvants, Immunologic/pharmacology , Animals , Chemistry Techniques, Synthetic/methods , Humans , Immunity, Innate , Models, Molecular , Toll-Like Receptors/immunology , Vaccines, Synthetic/immunology , Vaccines, Synthetic/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...